EBV-specific cytotoxic T-lymphocytes (Bellicum Pharmaceuticals)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameEBV-specific cytotoxic T-lymphocytes (Bellicum Pharmaceuticals)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Antigen > Tumor antigen

Mechanisms of ActionT lymphocytes stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBellicum Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBellicum Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A